A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and a favorable safety profile. The therapy's quarterly dosing and potential for broader autoimmune indications support its different…
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and a favorable safety profile. The therapy's quarterly dosing and potential for broader autoimmune indications support its differentiation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
